Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1;35(11):1973-1983.
doi: 10.1093/ndt/gfaa261.

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Luuk B Hilbrands  1 , Raphaël Duivenvoorden  1 , Priya Vart  2   3   4 , Casper F M Franssen  4 , Marc H Hemmelder  5 , Kitty J Jager  6 , Lyanne M Kieneker  4 , Marlies Noordzij  4 , Michelle J Pena  7 , Hanne de Vries  4 , David Arroyo  8 , Adrian Covic  9 , Marta Crespo  10 , Eric Goffin  11 , Mahmud Islam  12 , Ziad A Massy  13   14 , Nuria Montero  15 , João P Oliveira  16 , Ana Roca Muñoz  17 , J Emilio Sanchez  18 , Sivakumar Sridharan  19 , Rebecca Winzeler  20 , Ron T Gansevoort  4 ; ERACODA Collaborators
Collaborators, Affiliations

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Luuk B Hilbrands et al. Nephrol Dial Transplant. .

Erratum in

Abstract

Background: Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population.

Methods: We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality.

Results: Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3-30.2%] in kidney transplant and 25.0% (95% CI 20.2-30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59-1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07-0.56, P < 0.01).

Conclusions: The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

Keywords: COVID-19; dialysis; kidney; mortality; transplantation.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Vital status at Day 28 after presentation with COVID-19 of (A) kidney transplant (n = 305) and (B) haemodialysis patients (n = 768).
FIGURE 2
FIGURE 2
Relationship between age, clinical frailty score and 28-day case-fatality rate in (A) kidney transplant and (B) dialysis patients with COVID-19. Age and clinical frailty scores are subdivided into three clinical classes.
FIGURE 3
FIGURE 3
Association of demographic factors, major cardiovascular disease risk factors and chronic lung disease with 28-day mortality in dialysis and kidney transplant patients with COVID-19. Results are shown for a full adjusted multivariate model that includes the covariates shown in the graphs to allow comparison with data from the literature. Panel (A) shows results for patients on dialysis. Panel (B) shows results for patients living with a kidney transplant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly ... (1 September 2020, date last accessed)
    1. Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239. - PubMed
    1. COVID-19 Cases and Case Fatality Rate by age. https://ec.europa.eu/knowledge4policy/sites/know4pol/files/jrc120420_cov... (6 October 2020, date last accessed)
    1. Goyal P, Choi JJ, Pinheiro LC. et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382: 2372–2374 - PMC - PubMed
    1. Myers LC, Parodi SM, Escobar GJ. et al. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA 2020; 323: 2195. - PMC - PubMed

Publication types

MeSH terms